Curio Wealth LLC Invests $104,000 in Johnson & Johnson (NYSE:JNJ)

Curio Wealth LLC acquired a new position in shares of Johnson & Johnson (NYSE:JNJ) during the 4th quarter, according to its most recent filing with the SEC. The institutional investor acquired 717 shares of the company’s stock, valued at approximately $104,000.

A number of other large investors also recently modified their holdings of the company. Cassady Schiller Wealth Management LLC raised its holdings in shares of Johnson & Johnson by 1.6% in the 4th quarter. Cassady Schiller Wealth Management LLC now owns 8,154 shares of the company’s stock worth $1,179,000 after purchasing an additional 128 shares during the period. TCTC Holdings LLC raised its holdings in shares of Johnson & Johnson by 0.5% in the 4th quarter. TCTC Holdings LLC now owns 61,153 shares of the company’s stock worth $8,844,000 after purchasing an additional 319 shares during the period. Arbor Capital Management Inc. ADV raised its holdings in shares of Johnson & Johnson by 4.5% in the 4th quarter. Arbor Capital Management Inc. ADV now owns 11,382 shares of the company’s stock worth $1,722,000 after purchasing an additional 494 shares during the period. Gold Investment Management Ltd. raised its holdings in shares of Johnson & Johnson by 1.0% in the 4th quarter. Gold Investment Management Ltd. now owns 17,389 shares of the company’s stock worth $2,515,000 after purchasing an additional 168 shares during the period. Finally, Creative Financial Designs Inc. ADV raised its holdings in shares of Johnson & Johnson by 7.6% in the 4th quarter. Creative Financial Designs Inc. ADV now owns 9,509 shares of the company’s stock worth $1,375,000 after purchasing an additional 668 shares during the period. 69.55% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, VP Robert J. Decker sold 6,999 shares of the company’s stock in a transaction on Tuesday, February 25th. The stock was sold at an average price of $165.88, for a total transaction of $1,160,994.12. Following the completion of the transaction, the vice president now directly owns 21,001 shares in the company, valued at $3,483,645.88. This represents a 25.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Timothy Schmid sold 403 shares of the stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total value of $62,928.45. Following the completion of the transaction, the executive vice president now directly owns 15,098 shares of the company’s stock, valued at $2,357,552.70. This trade represents a 2.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.16% of the stock is owned by company insiders.

Analysts Set New Price Targets

JNJ has been the topic of a number of recent research reports. Raymond James reduced their price objective on Johnson & Johnson from $170.00 to $165.00 and set an “outperform” rating on the stock in a research note on Thursday, January 23rd. Royal Bank of Canada reiterated an “outperform” rating and set a $181.00 target price on shares of Johnson & Johnson in a report on Wednesday, February 19th. Guggenheim reiterated a “neutral” rating on shares of Johnson & Johnson in a report on Monday, March 10th. Stifel Nicolaus dropped their target price on Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating on the stock in a report on Thursday, January 23rd. Finally, Leerink Partners dropped their target price on Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating on the stock in a report on Thursday, January 23rd. Nine research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $171.33.

Johnson & Johnson Stock Performance

Shares of Johnson & Johnson stock opened at $162.94 on Monday. The firm has a market cap of $392.29 billion, a PE ratio of 24.50, a price-to-earnings-growth ratio of 2.56 and a beta of 0.47. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $169.99. The firm’s 50-day simple moving average is $154.98 and its 200-day simple moving average is $156.27. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, topping the consensus estimate of $1.99 by $0.05. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The firm had revenue of $22.52 billion for the quarter, compared to analyst estimates of $22.44 billion. During the same quarter in the prior year, the business earned $2.29 earnings per share. Johnson & Johnson’s quarterly revenue was up 5.3% on a year-over-year basis. Equities analysts forecast that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th were paid a dividend of $1.24 per share. The ex-dividend date of this dividend was Tuesday, February 18th. This represents a $4.96 dividend on an annualized basis and a yield of 3.04%. Johnson & Johnson’s payout ratio is currently 74.59%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.